Absci Corp (ABSI) Stock Analysis
Verdict: WATCH (do not buy)
Eli Lilly-backed ABS-201 pipeline pivot extends cash into 2H 2028, but 997x P/S valuation hinges entirely on 2H 2026 Phase 1 AGA data.
Investment score: 53/100
Analysis as of
Is Absci Corp stock worth reviewing? AI model thesis
The AI model recommends watching Absci Corp. A $100M capital raise in June 2026 with Eli Lilly participation provides financial runway through 2H 2028, but a 997x P/S multiple leaves zero room for error ahead of 2H 2026 ABS-201 Phase 1 trial updates.
7-factor investment score
- Valuation: 25/100 (weight 20%)
- Financial Health: 55/100 (weight 15%)
- Technical Momentum: 70/100 (weight 15%)
- Earnings Quality: 50/100 (weight 15%)
- Insider Sentiment: 65/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 45/100 (weight 15%)
Absci Corp opportunities and risks
What speaks for ABSI
- Strategic validation and $40M investment from Eli Lilly in June 2026 underpins lead asset ABS-201.
What speaks against ABSI
- Extreme valuation exposure represented by a TTM Price-to-Sales ratio of 997.14x vs peer median of 17.67x.
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| ABSI | n/a | 997.1x | n/a | -255.9% | -7756.4% | -7.0% |
| ZYME | n/a | 52.0x | n/a | 87.8% | -404.0% | -6.2% |
| COAG | n/a | 0.0x | n/a | 0.0% | 0.0% | -2.8% |
| XNCR | n/a | 17.7x | n/a | 43.3% | -155.6% | -11.2% |
| RARE | n/a | 2.2x | n/a | 83.1% | -81.8% | -31.0% |
| TRAX | n/a | 0.0x | n/a | 0.0% | 0.0% | -7.0% |
| Peer median | n/a | 2.2x | n/a | 43.3% | -81.8% | -7.0% |
Frequently asked questions about Absci Corp (ABSI)
Is ABSI stock a good investment?
The cached TradeMates AI model rates Absci Corp as WATCH (do not buy) with an investment score of 53/100. The AI model recommends watching Absci Corp. A $100M capital raise in June 2026 with Eli Lilly participation provides financial runway through 2H 2028, but a 997x P/S multiple leaves zero room for error ahead of 2H 2026 ABS-201 Phase 1 trial updates. This is algorithmic model output, not personal investment advice.
Is ABSI stock a buy?
The TradeMates model verdict for ABSI is WATCH (do not buy) with an investment score of 53/100. Treat this as a model signal to review, not a personal buy recommendation.